FDA Approves Rocket Pharma Kresladi: First Gene Therapy for LAD-I
Rocket Pharmaceuticals received FDA accelerated approval on March 26, 2026 for Kresladi, the first gene therapy for severe LAD-I, along with a Rare Pediatric Disease Priority Review Voucher worth an estimated $100M–$150M.
Arevon Breaks Ground on $600M 250-MW California Battery Project
Arevon Energy started construction on the $600 million, 250-MW/1,000-MWh Cormorant Energy Storage Project in Daly City on March 24, 2026, under a long-term offtake with MCE serving 1.8 million customers.